Cy­to­ki­net­ics’ ALS drug fails PhI­II, leav­ing the biotech with a sin­gle late-stage prospect

Cy­to­ki­net­ics’ can­di­date for the mus­cle dis­ease amy­otroph­ic lat­er­al scle­ro­sis, or ALS, failed a Phase III tri­al, the Bay Area biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.